Abdi Ibrahim granted permission to manufacture COVID-19 vaccine

Turkey’s leading pharma company, Abdi Ibrahim, has been given the manufacturing permit for COVID-19 vaccines, after proving its capacity to manufacture with the highest standards. Abdi Ibrahim’s Chairman of the Board of Directors, Nezih Barut, stated, “This permit, granted to us following the audits conducted by the Ministry of Health officials, proves that we are capable of manufacturing vaccines according to global standards”.

Conducting its activities in the Turkish pharmaceuticals industry for 109 years, and as the market leader for the last 19 years, Abdi Ibrahim has recently been given the permit to manufacture, fill and finish COVID-19 vaccines, a testament to its capacity to manufacture at the highest standards.

Chairman of the Board of Directors at Abdi Ibrahim, Nezih Barut, revealed that following the inspections and audits conducted by the Ministry of Health officials, Abdi Ibrahim was given the permit to manufacture mRNA-based and inactivated vaccines, and to perform the fill and finish process. He went on to say, “In December, we obtained the permit from the Ministry of Health to manufacture and to fill and finish both mRNA and inactivated vaccines for human use. For the manufacturing, as well as the fill and finish of vaccines, a sturdy infrastructure and an effective quality management system are necessary. This permit, given following the inspections conducted by the Ministry, once again certifies the competency of AbdiBio facility and our capacity to manufacture vaccines.”

After highlighting that Abdi Ibrahim has been offering its R&D and manufacturing power and its medical competencies, expertise and experiences to the service of Turkish medicine and patients in the fight against the pandemic, Nezih Barut continued with remarks on the manufacturing of the vaccine: “As a leader in our industry, we prioritized the needs of our nation and contributed to the fight with the best of our ability. While closely monitoring the global progress in vaccine development, we also applied to the Ministry of Health to obtain the permit to manufacture different varieties of the COVID-19 vaccine in the facilities at Abdi Ibrahim, Turkey’s national pharma company. Following the inspections, our AbdiBio facility obtained the permit to manufacture and to fill and finish both the mRNA-based biotechnical vaccines, manufactured by BioNTech and Moderna, and the inactivated vaccines manufactured by Russian and Chinese companies. This permit has proven that both our infrastructure and quality management systems are of high-quality.”

Emphasizing that Abdi Ibrahim has the necessary technology and infrastructure to manufacture and to fill and finish vaccines, Barut said “We have made considerable investments in biotechnology, an area to which we attribute great strategic importance and consider to be the future of pharmaceuticals. Our biotech medicine production facility, AbdiBio, completed in 2018, is the biggest step we have taken so far in this area. The goal of all the investments we make in biotechnology, including the manufacturing of vaccines, is to turn Turkey into a manufacturing center and a key player in this strategic area. Currently Abdi Ibrahim has the capacity to manufacture 20 million vaccines. If any additional investments are needed to manufacture more COVID-19 vaccines, we are ready to invest more in a short amount of time.”
 

For Information:

Hill + Knowlton Strategies +90 212 270 52 32 

Bülent Değerli: Media Director+90 545 233 24 28 / [email protected] 

Mustafa Salih: Media Director+90 536 863 19 04 / [email protected]